HUP0003053A2 - A 33-epiklór-33-dezoxi-aszkomicin kristályos formái, eljárás ezek előállítására és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

A 33-epiklór-33-dezoxi-aszkomicin kristályos formái, eljárás ezek előállítására és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0003053A2
HUP0003053A2 HU0003053A HUP0003053A HUP0003053A2 HU P0003053 A2 HUP0003053 A2 HU P0003053A2 HU 0003053 A HU0003053 A HU 0003053A HU P0003053 A HUP0003053 A HU P0003053A HU P0003053 A2 HUP0003053 A2 HU P0003053A2
Authority
HU
Hungary
Prior art keywords
forms
compound
formula
epichloro
crystallization
Prior art date
Application number
HU0003053A
Other languages
English (en)
Inventor
Cornelia Dosenbach
Maximilian Grassberger
Otto Hartmann
Amarylla Horvath
Jean-Paul Mutz
Gerhard Penn
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10815103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0003053(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0003053A2 publication Critical patent/HUP0003053A2/hu
Publication of HUP0003053A3 publication Critical patent/HUP0003053A3/hu
Publication of HU227755B1 publication Critical patent/HU227755B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgya az (I) általános képletű 33-epiklór-33-dezoxi-aszkomicin és különböző tautomer vagy szolvatált formái kristályosalakban, így például A és B kristályformában. Az előállítás oly módontörténik, hogy egy (I) képletű amorf vegyületet vagy (I) képletű, az Akristályformától eltérő vegyületet, illetve (I) képletű, a Bkristályformától eltérő vegyületet ennek oldatában kristályosodásrakésztető körülmények között, vagy az A, illetve B formakristályosodására nézve preferenciálisan kristályosításra késztetőkörülmények között megfelelően átalakítanak. Ilyen kristályosvegyületet különösen topikálisan alkalmazható galenikus gyógyászatikészítményekben, például krémekben, emulziókban és kenőcsökbenhasználhatók. Ó
HU0003053A 1997-06-30 1998-06-26 Crystalline forms of 33-epichloro-33-desoxyascomycin, process for their preparation and pharmaceutical compositions containing them HU227755B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9713730.1A GB9713730D0 (en) 1997-06-30 1997-06-30 Organic compounds
PCT/EP1998/003929 WO1999001458A1 (en) 1997-06-30 1998-06-26 Crystalline macrolides and process for their preparation

Publications (3)

Publication Number Publication Date
HUP0003053A2 true HUP0003053A2 (hu) 2001-02-28
HUP0003053A3 HUP0003053A3 (en) 2003-03-28
HU227755B1 HU227755B1 (en) 2012-02-28

Family

ID=10815103

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003053A HU227755B1 (en) 1997-06-30 1998-06-26 Crystalline forms of 33-epichloro-33-desoxyascomycin, process for their preparation and pharmaceutical compositions containing them

Country Status (32)

Country Link
US (1) US6423722B1 (hu)
EP (1) EP0994880B1 (hu)
JP (2) JP3880634B2 (hu)
KR (1) KR100399765B1 (hu)
CN (1) CN1139595C (hu)
AR (1) AR017754A1 (hu)
AT (1) ATE287410T1 (hu)
AU (1) AU739211B2 (hu)
BR (1) BR9810956A (hu)
CA (1) CA2290412C (hu)
CO (1) CO4940463A1 (hu)
CZ (1) CZ297244B6 (hu)
DE (1) DE69828692T2 (hu)
DK (1) DK0994880T3 (hu)
ES (1) ES2236922T3 (hu)
GB (1) GB9713730D0 (hu)
HK (1) HK1028597A1 (hu)
HU (1) HU227755B1 (hu)
ID (1) ID24897A (hu)
IL (1) IL132761A0 (hu)
MY (1) MY118718A (hu)
NO (1) NO312765B1 (hu)
NZ (1) NZ500994A (hu)
PE (1) PE97699A1 (hu)
PL (1) PL192761B1 (hu)
PT (1) PT994880E (hu)
RU (1) RU2219181C2 (hu)
SK (1) SK285665B6 (hu)
TR (1) TR199903189T2 (hu)
TW (1) TW552264B (hu)
WO (1) WO1999001458A1 (hu)
ZA (1) ZA985655B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
GB0125443D0 (en) * 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
US7875630B2 (en) * 2003-09-03 2011-01-25 Glaxo Group Limited Process salts compositions and use
EP1817314A1 (en) * 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Non-hygroscopic and powdery amorphous pimecrolimus
WO2008057511A2 (en) * 2006-11-06 2008-05-15 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
WO2008073757A1 (en) * 2006-12-07 2008-06-19 Helsinn Healthcare Sa Crystalline and amorphous forms of palonosetron hydrochloride
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
ES2550634T3 (es) 2009-07-10 2015-11-11 Boston Scientific Scimed, Inc. Uso de nanocristales para un balón de suministro de fármaco
US10080821B2 (en) 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013022458A1 (en) * 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
WO2014145780A1 (en) 2013-03-15 2014-09-18 Biosensors International Group, Ltd. Purification of rapamycin derivatives
EP3178824A1 (en) 2015-12-08 2017-06-14 Medichem, S.A. Process for preparing pimecrolimus
CA3060330A1 (en) * 2017-05-01 2018-11-08 Meda Pharma Gmbh & Co. Kg Process to convert crude ascomycin into purified pimecrolimus
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
WO2024209038A1 (en) 2023-04-06 2024-10-10 Premark Pharma Gmbh Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
CY1306A (en) 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
JP2728482B2 (ja) * 1989-01-26 1998-03-18 協和醗酵工業株式会社 マクロライド系抗生物質の精製法
WO1991000865A1 (en) 1989-07-10 1991-01-24 Gema S.A. A novel stable form of cephradine, process for its production and intermediates used therein
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
JPH05505798A (ja) * 1990-03-13 1993-08-26 フアイソンズ・ピーエルシー 免疫抑制マクロ環状化合物
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
EP0480623A1 (en) * 1990-10-11 1992-04-15 Merck & Co. Inc. New halomacrolides and derivatives having immunosuppressive activity
ES2100291T3 (es) 1991-07-30 1997-06-16 Ajinomoto Kk Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos.
US5247076A (en) 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
US5626757A (en) * 1994-02-22 1997-05-06 Advanced Separation Technologies Inc. Macrocyclic antibiotics as separation agents
AU6900596A (en) * 1995-08-24 1997-03-19 Merck & Co., Inc. Process for the preparation of imidazolyl macrolide immunosuppressants
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds

Also Published As

Publication number Publication date
SK285665B6 (sk) 2007-05-03
US6423722B1 (en) 2002-07-23
DK0994880T3 (da) 2005-05-30
GB9713730D0 (en) 1997-09-03
IL132761A0 (en) 2001-03-19
CZ474099A3 (cs) 2000-04-12
CZ297244B6 (cs) 2006-10-11
JP4504323B2 (ja) 2010-07-14
PT994880E (pt) 2005-06-30
JP3880634B2 (ja) 2007-02-14
DE69828692T2 (de) 2006-01-12
TR199903189T2 (xx) 2000-06-21
AR017754A1 (es) 2001-10-24
ZA985655B (en) 1998-12-30
NO995909D0 (no) 1999-12-02
JP2006151999A (ja) 2006-06-15
KR20010020423A (ko) 2001-03-15
CA2290412A1 (en) 1999-01-14
PE97699A1 (es) 1999-10-29
TW552264B (en) 2003-09-11
AU8540998A (en) 1999-01-25
ID24897A (id) 2000-08-31
PL336719A1 (en) 2000-07-03
WO1999001458A1 (en) 1999-01-14
RU2219181C2 (ru) 2003-12-20
BR9810956A (pt) 2000-09-26
HK1028597A1 (en) 2001-02-23
NZ500994A (en) 2001-08-31
MY118718A (en) 2005-01-31
EP0994880B1 (en) 2005-01-19
JP2001506279A (ja) 2001-05-15
AU739211B2 (en) 2001-10-04
ATE287410T1 (de) 2005-02-15
HU227755B1 (en) 2012-02-28
NO995909L (no) 1999-12-02
PL192761B1 (pl) 2006-12-29
SK186699A3 (en) 2000-05-16
DE69828692D1 (de) 2005-02-24
CN1261365A (zh) 2000-07-26
KR100399765B1 (ko) 2003-09-29
CO4940463A1 (es) 2000-07-24
CA2290412C (en) 2009-11-10
NO312765B1 (no) 2002-07-01
ES2236922T3 (es) 2005-07-16
EP0994880A1 (en) 2000-04-26
HUP0003053A3 (en) 2003-03-28
CN1139595C (zh) 2004-02-25

Similar Documents

Publication Publication Date Title
HUP0003053A2 (hu) A 33-epiklór-33-dezoxi-aszkomicin kristályos formái, eljárás ezek előállítására és az ezeket tartalmazó gyógyszerkészítmények
ATE202109T1 (de) Kristallines ceftiofur (freie säure)
TR200001545T2 (tr) Plazma proteini içeren farmasötik bileşimler.
HUP0100397A2 (hu) Tetrahidro- vagy oktahidrobenzo-naftiridin és kinolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
YU22000A (sh) Biciklični inhibitori kinaze
KR970027079A (ko) (r)-(-)-2-{n-[4-(1,1-디옥시도-3-옥소-2,3-디히드로-벤즈이소티아졸-2-일)-부틸]-아미노메틸}-크로만의 결정성 염산염
BR0015836A (pt) Cristal de 4-carboxiamino-2-etil-1,2,3,4-tetra-hidroquinolina como inibidor de cetp
HUP0200580A2 (hu) Celecoxib polimorf kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0100865A2 (hu) Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
HUP9802121A2 (hu) Imidazolinszármazékok, eljárás előállításukra és e vegyületeket tartalmazó gyógyszerkészítmények
HUP0200055A2 (hu) 16-Hidroxi-ösztratriének és ezeket tartalmazó gyógyszerkészítmények
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
ATE171943T1 (de) Piperidin-verbindungen, ihre darstellung und ihre verwendung
IL131216A (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
NO984921L (no) Tienopyridinderivater og deres anvendelser
NZ220967A (en) 4-nitrogen substituted isoquinolin-3-ol derivatives and pharmaceutical compositions
HUP0001402A2 (hu) 6,7-Diszubsztituált-4-aminopirido[2,3-d] pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUP0004177A2 (hu) 4,5-Diaril-oxazol származékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
ATE154027T1 (de) Glycosylamide von 2-aminoacylamino-2-desoxy- zuckern
ECSP982561A (es) Macrolidas cristalinas
TH14687A (th) กรรมวิธีสำหรับเตรียมอนุพันธ์ต่าง ๆ ของเฮเทอโรไซเคิลซับสทิทิวเทด เบนซีนมีเธนแอมีน
TH14687EX (th) กรรมวิธีสำหรับเตรียมอนุพันธ์ต่าง ๆ ของเฮเทอโรไซเคิลซับสทิทิวเทด เบนซีนมีเธนแอมีน

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MEDA PHARMA S.A.R.L., LU

Free format text: FORMER OWNER(S): NOVARTIS AG., CH